Dudediligence.

Cartesian Therapeutics, Inc

RNACNASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

30.0M

on 2026-06-30, from 5.52M on 2024-03-31 10-Q ↗

10M20M30MMar2024JunSepDecMar2025JunSepDecMar2026Jun

Newest

S-3 of 2024-12-13. Not read yet. S-3 ↗

$100.0M

Leerink Partners, agreement of 2024-12-13. No at-the-market sales statement read from a 10-Q or 10-K. 424B3 ↗

Warrants

692K

Warrants of every class as tagged in the XBRL facts on 2026-06-30, exercise price $46.76. 10-Q ↗

Cash

7.7 quarters

$147.6M on 2026-06-30 ÷ $19.1M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 6 of its filings are not read yet.

Also on file: up to $25.0M term loans agreed 2026-05-22 8-K ↗